Clinical Trial Update: Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of RO7239361 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• BMS-986089 (BMS-986089)
• RO7239361

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Muscular Dystrophy (DMD) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-05-08